Ro 16-6028: a novel anxiolytic acting as a partial agonist at the benzodiazepine receptor.
Martin
J R
JR
Pharmaceutical Research Department, F. Hoffmann-La Roche & Co., Ltd., Basel, Switzerland.
Pieri
L
L
Bonetti
E P
EP
Schaffner
R
R
Burkard
W P
WP
Cumin
R
R
Haefely
W E
WE
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D000927:Anticonvulsants; D001522:Behavior, Animal / Q000187:drug effects*; D001570:Benzodiazepinones / Q000494:pharmacology*; D002415:Cats; D003220:Conflict, Psychological; D006152:Cyclic GMP / Q000378:metabolism; D003975:Diazepam / Q000037:antagonists & inhibitors; D004285:Dogs; D005445:Flunitrazepam / Q000037:antagonists & inhibitors; D051379:Mice; D051381:Rats; D011963:Receptors, GABA-A / Q000187:drug effects*; D012453:Saimiri; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology
D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D001570:Benzodiazepinones; D011963:Receptors, GABA-A; D005445:Flunitrazepam; D006152:Cyclic GMP; C054626:bretazenil; D003975:Diazepam